Table 2 Probability (95 % CI) of no metastasis as a function of time
Time (years) | 2 | 4 | 6 | 8 | HR |
|---|---|---|---|---|---|
A. Four sample subsets defined by Miettinen risk score (Fig. 3a, p < 0.001) | |||||
High risk, n = 17 | 0.53 (0.34–0.83) | 0.28 (0.12–0.68) | 0.28 (0.12–0.68) | 0.28 (0.12–0.68) | 3.4 (1.1, 10.9) |
Intermediate risk, n = 14 | 0.93 (0.80–1.00) | 0.85 (0.68–1.00) | 0.68 (0.42–1.00) | 0.68 (0.42–1.00) | Reference group |
Low risk, n = 16 | NR | NR | NR | No follow-up | Not estimable |
Very low risk, n = 13 | NR | NR | NR | NR | Not estimable |
B. Two sample subsets among the high- and intermediate-risk samples defined by the AF-gene set in Fig. 1a (Fig. 3b, p = 0.01) | |||||
Good group, n = 8 | NR | NR | No follow-up | No follow-up | Reference group |
Bad group, n = 23 | 0.61 (0.44–0.85) | 0.39 (0.22–0.68) | 0.32 (0.17–0.63) | 0.32 (0.17–0.63) | Not estimable |
C. Two sample subsets among the high- and intermediate-risk samples defined by the OVCA-gene set in Fig. 1B (Fig. 3C, p < 0.001) | |||||
Good group, n = 14 | NR | 0.93 (0.80–1.00) | 0.93 (0.80–1.00) | 0.93 (0.80–1.00) | Reference group |
Bad group, n = 17 | 0.47 (0.28-0.78) | 0.20 (0.06–0.63) | 0.10 (0.02–0.61) | 0.10 (0.02–0.61) | 19.9 (2.6–154.0) |
D. Two sample subsets among the high- and intermediate-risk samples defined by the RCC-gene set in Fig. 1c (Fig. 3d, p = 0.045) | |||||
Good group, n = 17 | 0.59 (0.40–0.88) | 0.38 (0.20–0.72) | 0.28 (0.12–0.67) | 0.28 (0.12–0.67) | 3.4 (1.0, 12.3) |
Bad group, n = 14 | 0.86 (0.69–1.00) | 0.78 (0.59–1.00) | No follow-up | No follow-up | Reference group |
E. Two sample subsets among the high- and intermediate-risk samples defined by the combined gene set in Fig. 1d (Fig. 3e, p = 0.06129). | |||||
Good group, n = 5 | NR | NR | No follow-up | No follow-up | Reference group |
Bad group, n = 26 | 0.65 (0.49–0.87) | 0.46 (0.29–0.72) | 0.38 (0.21–0.68) | 0.38 (0.21–0.68) | Not estimable |